|
Showing 1 - 15 of
15 matches in All Departments
Cancer is extremely common and in many situations a truly
frightening disease, but the psychological aspects and effects have
frequently been ignored. Patrice Guex reviews current thinking on
the subject of possible psychosomatic causes of cancer, on the
emotional or psychological reactions that it provokes, and on the
medical treatment available. Illustrated with 11 case histories,
this work aims to deal with the reactions of cancer patients to
their illness, and the ways in which they can be helped in the
hospital setting, at the same time having regard for their human
dignity. In the context of a multidisciplinary approach that takes
account of medical treatments as well as psychological
interventions, the author suggests better ways of communicating in
order to provide a therapeutic partnership between carer and
client. Every aspect of cancer care, including pain relief,
psycho-pharmology and complementary medicine, is considered, paying
special attention to the needs of terminal patients and their
carers.
Translated by: Heather Goodare
The development of drug-resistant cancers is considered to be the
most significant obstacle to the cure of cancer today. Nearly half
of all patients with cancer suffer from tumours that are
intrinsically resistant to chemotherapy, and most of the remaining
half develop drug resistance during the course of their treatment.
This book reviews the mechanisms and clinical implications of drug
resistance in cancer with unrivalled authority. Chapters cover
topics of current clinical concern, including multiple drug
resistance and its reversal, topoisomerase drugs, apoptosis, dose
intensity and escalation, gene therapy and haematopoietic support.
The authors are among the leading clinicians and investigators in
the field. These authoritative volumes in this series are intended
for a wide audience of clinicians and researchers with an interest
in the applications of biomedical science to the understanding and
management of cancer.
Treatment of Cancer is a multi-author work and comprehensive guide
on modern cancer treatment that aims to give clinician and student
alike the framework for an integrated approach to patient care,
including radiotherapy, chemotherapy, and surgery. Much information
is presented in tables and charts for easy assimilation, and clear
algorithms for patient pathways are included to make decisions
straightforward while allowing for sound clinical judgement.
This 2006 book examines the interaction of economics and the
delivery of cancer care in the global context. It analyses the
causes of tension between those paying for care, those providing
the care and those marketing drugs and devices. The concept and
requirement for rationing is examined in different economic
environments. As cancer increases in incidence and prevalence, the
economics of providing care becomes a more important subject than
ever before. Written by a leading health economist and oncologist,
this was the first comprehensive book on the economics of cancer
care continues to be of interest to health professionals and policy
makers alike.
This 1996 volume reviewed advances in the field of human tumour
immunology, particularly in relation to the potential for immune
intervention in preventing or treating tumours. The editors and
contributors, all prominent workers in the field, survey advances
in the understanding of the relationship between the cancer cell
and the immune response at the time of publication. Chapters review
in depth the function of immune surveillance and mechanisms of
tumour immunity, the role of T lymphocytes and oncogenes in the
immune response to cancer, and the potential for immunotherapy of
cancer. Areas of tumour immunology that were new at the time of
this book's publication are presented, including progress in the
development of tumour vaccines with particular reference to
melanoma. The volumes in this series are intended for a wide
audience of clinicians and researchers with an interest in the
applications of biomedical science to the understanding and
management of cancer.
Interferon was first discovered in 1957. Over the last five years
it has become almost a household word. Many believe it to be a drug
with already proven efficacy against cancer and viral infection.
The media has distorted any cool scientific view of the data
available. We have learned much about the complexity of the
interferon system. We know some of the switches involved in
interferon gene expression and its secretion by virally and immune
stimulated cells. We also know that it binds to a cell surface
receptor, mediating its complex effects on target cells by a series
of second messengers. The advent of the new techniques of modern
molecular biology, such as monoclonal antibodies and gene cloning,
has had tremendous impact on the rate of acquisition of knowledge.
Such techniques have provided us with almost unlimited quantities
of highly purified interferon for clinical trial in patients with a
spectrum of infectious and malignant diseases. The information we
have gathered raises many more questions. Why should there be
several families of interferon genes? What is their true physiolo
gical role? How are they interrelated functionally? Interferon is
clearly a cellular hormone providing a means of communication
between cells. fhether it has clinical value in the management of
patients with diseased cells remains to be seen. This book sum
marises our current knowledge of interferons as possible an- cancer
agents. It is clear interferon is no penicillin for cancer."
This 1996 volume reviewed advances in the field of human tumour
immunology, particularly in relation to the potential for immune
intervention in preventing or treating tumours. The editors and
contributors, all prominent workers in the field, survey advances
in the understanding of the relationship between the cancer cell
and the immune response at the time of publication. Chapters review
in depth the function of immune surveillance and mechanisms of
tumour immunity, the role of T lymphocytes and oncogenes in the
immune response to cancer, and the potential for immunotherapy of
cancer. Areas of tumour immunology that were new at the time of
this book's publication are presented, including progress in the
development of tumour vaccines with particular reference to
melanoma. The volumes in this series are intended for a wide
audience of clinicians and researchers with an interest in the
applications of biomedical science to the understanding and
management of cancer.
The Advances in Cancer Research series provides invaluable
information on the exciting and fast-moving field of cancer
research. This volume stands as the first ever thematic volume in
the series, focusing on the topic of genomics in cancer drug
development. The chapters included in this book represent the
cutting-edge information in the field and span such topics as Mass
Spectrometry: Uncovering the Cancer Proteome for Diagnostics;
Biomarker Discovery in Epithelial Ovarian Cancer by Genomic
Approaches; The Application of siRNA Technology to Cancer Biology
Discovery; Ribozyme Technology for Cancer Gene Target
Identification and Validation; Cancer Cell-Based Genomic and Small
Molecule Screens; Tumour Antigens as Surrogate Markers and Targets
for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer
Models in Drug Discovery; Biomarker Assay Translation from
Discovery to Clinical Studies in Cancer Drug Development -
Quantification of Emerging Protein Biomarkers; Molecular Optical
Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in
the United States, Europe and Japan.
This 2006 book examines the interaction of economics and the
delivery of cancer care in the global context. It analyses the
causes of tension between those paying for care, those providing
the care and those marketing drugs and devices. The concept and
requirement for rationing is examined in different economic
environments. As cancer increases in incidence and prevalence, the
economics of providing care becomes a more important subject than
ever before. Written by a leading health economist and oncologist,
this was the first comprehensive book on the economics of cancer
care continues to be of interest to health professionals and policy
makers alike.
The development of drug-resistant cancers is considered to be the
most significant obstacle to the cure of cancer today. Nearly half
of all patients with cancer suffer from tumours that are
intrinsically resistant to chemotherapy, and most of the remaining
half develop drug resistance during the course of their treatment.
This book reviews the mechanisms and clinical implications of drug
resistance in cancer with unrivalled authority. Chapters cover
topics of current clinical concern, including multiple drug
resistance and its reversal, topoisomerase drugs, apoptosis, dose
intensity and escalation, gene therapy and haematopoietic support.
The authors are among the leading clinicians and investigators in
the field. These authoritative volumes in this series are intended
for a wide audience of clinicians and researchers with an interest
in the applications of biomedical science to the understanding and
management of cancer.
The street-wise patient's guide to surviving cancer.How to be an
active, organised, informed, and welcomed patient.The author is an
internationally-famous cancer doctor. Former Chief, World Health
Organisation. Cancer Programme. How to survive, and live with,
cancer.iE Short, sharp practical guide.iE Shows patients how to can
take control of their care. iE How to get the system to work for
you. iE Gives 100 advisory websites, with expert notes. iE
Absolutely up-to-date.
Treatment of Cancer is a multi-author work and comprehensive guide
on modern cancer treatment that aims to give clinician and student
alike the framework for an integrated approach to patient care,
including radiotherapy, chemotherapy, and surgery. Much information
is presented in tables and charts for easy assimilation, and clear
algorithms for patient pathways are included to make decisions
straightforward while allowing for sound clinical judgement.
|
You may like...
Ab Wheel
R209
R149
Discovery Miles 1 490
Loot
Nadine Gordimer
Paperback
(2)
R383
R318
Discovery Miles 3 180
|